When most people think of Parkinson’s disease, they picture the characteristic tremor—that involuntary shaking that has become almost synonymous with the condition. But the reality is far more complex than just one visible symptom. Let’s dig into what’s actually happening in the brain, how doctors figure out what’s going on, and what living with this condition really looks like.
What Causes Parkinson’s Disease?
Here’s where things get frustrating for researchers: despite decades of study, scientists still don’t know exactly what causes the nerve cells in the brain to die. I’m going to apologize in advance because I’m going to be using a lot of “doctor talk”—no way around it.
What we do know is that nerve cells (neurons) in the substantia nigra portion of the basal ganglia—an area of the brain controlling movement—become impaired or die, and these neurons normally produce dopamine, an important brain chemical. When these cells stop working properly, dopamine levels drop, and that’s when movement problems begin showing up.
But dopamine isn’t the whole story. People with Parkinson’s also lose nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which helps explain why the disease affects so much more than just movement—things like blood pressure, digestion, and energy levels all take a hit.
Most Parkinson’s cases are idiopathic, meaning the cause is unknown, though contributing factors have been identified. Current thinking suggests a complicated mix of genetic and environmental factors. About 5% to 10% of cases begin before age 50, and these early-onset forms are often, though not always, inherited.
Some risk factors have emerged from research: age is the most significant, with about 1% of those over 65 and around 4.3% of those over 85 affected. Traumatic brain injury significantly increases risk, especially if recent, and repeated head injuries from contact sports can cause what’s called post-traumatic parkinsonism. Muhammad Ali is a classic example of this.
Exposure to pesticides and industrial chemicals has also been identified as a risk factor. Interestingly, large epidemiologic studies consistently show that people who smoke have a lower risk of being diagnosed with Parkinson’s disease than never‑smokers, although smoking is still strongly discouraged because of its many harmful health risks. Large cohort studies in the U.S. and Europe generally find no direct association between alcohol consumption and Parkinson’s disease. A few observational studies show that moderate drinkers have slightly lower Parkinson’s rates. However, researchers believe this may be due to reverse causation (people in early or undiagnosed stages often reduce drinking because of GI or mood changes) and lifestyle confounders (moderate drinkers may differ in socioeconomic status, diet, or activity level). So, the “protective” effect is considered speculative, not causal.
The Symptoms: More Than Just Shaking
The hallmark movement symptoms—what doctors call “motor symptoms”—are what usually bring people to the doctor. Slowed movements, called bradykinesia, is required for a Parkinson’s diagnosis. People describe it as muscle weakness, though it’s really about control, not strength. The classic tremor, stiffness, and balance problems round out the main movement issues. Patients frequently show reduced arm swing, shuffling gait, difficulty initiating movement or turning, masked facial expression, decreased blinking, and soft or monotone speech.
But here’s what often surprises people: many individuals later diagnosed with Parkinson’s notice that prior to experiencing stiffness and tremor, they had sleep problems, constipation, loss of smell, and restless legs. These “prodromal symptoms” can show up years before the movement problems become obvious. Other early signs include mood disorders like anxiety and depression.
The cognitive side deserves attention too. Some people experience changes in cognitive function, including problems with memory, attention, and the ability to plan and accomplish tasks, though hard to pin down due to concurrence with age related memory problems, 20% at the time of diagnosis is a commonly cited number. More contested is how many develop Parkinson’s dementia, with estimates ranging from 20% all the way to 85%.
How Doctors Make the Diagnosis
Here’s something that might surprise you: there are currently no blood or laboratory tests to diagnose non-genetic cases of Parkinson’s. The standard diagnosis is clinical, meaning there’s no test that can give a conclusive result—certain physical symptoms need to be present.
Doctors typically diagnose Parkinson’s by taking a detailed medical history and performing a neurological examination. If symptoms improve after starting medication, that’s another indicator that the person has Parkinson’s.
There are some imaging tools available. The FDA approved an imaging scan called the DaTscan in 2011, which allows doctors to see detailed pictures of the brain’s dopamine system using a radioactive drug and SPECT scanner. But this scan can’t definitively diagnose Parkinson’s though it helps rule out conditions that mimic it. A hallmark of Parkinson’s is the buildup of misfolded alpha-synuclein proteins (Lewy bodies) inside neurons. Whether this is a cause, an effect, or both is still under study—this part of the science remains somewhat speculative.
Recently, researchers developed something more promising: the alpha-synuclein seeding amplification assay can detect abnormal alpha-synuclein in spinal fluid and may detect Parkinson’s in people who haven’t been diagnosed yet. The catch? It requires a spinal tap and isn’t widely available, though scientists are working on blood and saliva tests.
The early diagnostic challenge is real. Many disorders can cause similar symptoms, and people with Parkinson’s-like symptoms from other causes are sometimes said to have parkinsonism, which includes conditions like multiple system atrophy and Lewy body dementia that require different treatments.
What to Expect: The Prognosis
Let’s address the big question: how does Parkinson’s affect life expectancy? The news here is better than you might think. The average life expectancy of a person with Parkinson’s is generally the same as for someone without the disease.
More specifically, average life expectancy has increased by about 55% since 1967, rising to more than 14.5 years from diagnosis. Modern treatments have made a huge difference. Research indicates that those with Parkinson’s and normal cognitive function appear to have a largely normal life expectancy.
That said, timing matters. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy, and males with Parkinson’s may have a greater reduction in life expectancy than females.
The disease is progressive, meaning it gets worse over time, but symptoms and progression vary from person to person, and neither you nor your doctor can predict which symptoms you’ll get, when, or how severe they’ll be. The tremor-dominant type usually has a more favorable prognosis than the hypokinetic type.
What actually causes death in advanced Parkinson’s? Advanced symptoms can cause falls, pressure ulcers, swallowing difficulties and general frailty, all of which are linked to death. Aspiration pneumonia—when you inhale food or liquid into the lungs—is the leading cause of death for people with Parkinson’s.
Managing the Disease
Currently, there’s no cure for Parkinson’s, but medications or surgery can improve many of the movement symptoms.
The gold standard medication is levodopa (often combined with carbidopa as Sinemet). Healthcare providers use levodopa cautiously and they commonly combine it with other medications to keep your body from processing it before it enters your brain. This helps avoid side effects like nausea, vomiting, and low blood pressure when standing up. The tricky part? Over time, the way your body uses levodopa changes, and it can lose effectiveness.
Beyond levodopa, doctors use MAO-B inhibitors and dopamine agonists. As the disease progresses, these medications become less effective and may cause involuntary muscle movements. When drugs stop working well, there are surgical options to treat severe motor symptoms.
The main surgical treatment today is called deep brain stimulation (DBS). It is the most important therapeutic advancement since the development of levodopa, and it’s been FDA-approved since the late 1990s A surgeon places thin metal wires called electrodes into one or both sides of the brain, in specific areas that control movement. A second procedure implants an impulse generator battery under the collarbone or in the abdomen. It is similar to a heart pacemaker and about the size of a stopwatch, this device delivers electrical stimulation to those targeted brain areas.
A new treatment that is being used is focused ultrasound. Guided by MRI, high-intensity, inaudible sound waves are emitted into the brain, and where these waves cross, they create high energy that destroys a very specific area connected to tremor. It’s considered non-invasive and the FDA has approved it for Parkinson’s tremor that doesn’t respond to medications.
Don’t underestimate lifestyle interventions either. Physical therapy can improve balance and address muscle stiffness, and regular exercise improves strength, flexibility, and balance. Eating a balanced diet helps—drinking plenty of water and eating enough fiber reduces constipation, while omega-3 fats and magnesium may boost cognition and help with anxiety.
Parkinson’s disease sits at the intersection of aging, genetics, environment, and biology. Diagnosis is clinical, progression is gradual and variable, and treatment has become increasingly sophisticated. While it remains incurable, early diagnosis, personalized medication plans, targeted therapies like DBS, and consistent exercise allow many people to maintain meaningful independence for years.
The key message from specialists? Treatment makes a major difference in keeping symptoms from having worse effects, and adjustments to medications and dosages can hugely impact how Parkinson’s affects your life.
America’s Healthcare Paradox: Why We Pay Double and Get Less
By John Turley
On January 5, 2026
In Commentary, Medicine
The healthcare debate in America often circles back to a fundamental question: should we move toward a single-payer system, or is our current mixed public-private model the better path forward? It’s a conversation that gets heated quickly, but when you strip away the politics and look at how different systems actually function around the world, some interesting patterns emerge.
What We Mean by Single-Payer
A single-payer healthcare system means that one entity—usually the government or a government-related organization—pays for all covered healthcare services. Doctors and hospitals can still be private (and usually are), but instead of dealing with dozens of different insurance companies, they bill one source. It’s a lot like Medicare, which is why proponents often call it “Medicare-for-all”.
The key thing to understand is that single-payer isn’t necessarily the same as socialized medicine. In Canada’s system, for instance, the government pays the bills, but doctors are largely in the private sector and hospitals are controlled by private boards or regional health authorities rather than being part of the national government. Compare that to the UK’s National Health Service, where many hospitals and clinics are government-owned and many doctors are government employees.
America’s Current Patchwork
The United States operates what might charitably be called a “creative” approach to healthcare—a complex mix of employer-sponsored private insurance, government programs like Medicare, Medicaid and the VA system, individual marketplace plans, and direct out-of-pocket payments. Government already pays roughly half of total US health spending, but benefits, cost-sharing, and networks vary widely between plans, with little overall coordination. In 2023, private health insurance spending accounted for 30 percent of total national health expenditures, Medicare covered 21 percent, and Medicaid covered 18 percent. Most of the remainder was either paid out of pocket by private citizens or was written off by providers as uncollectible.
Here’s where it gets expensive. U.S. health care spending grew 7.5 percent in 2023, reaching $4.9 trillion or $14,570 per person, accounting for 17.6 percent of the nation’s GDP, and national health spending for 2024 is expected to have exceeded $5.3 trillion or 18% of GDP, and health spending is expected to grow to 20.3 percent of GDP by 2033.
For a typical American family, the costs are real and rising. In 2024, the estimated cost of healthcare for a family of four in an employer-sponsored health plan was $32,066.
The European Landscape
Europe doesn’t have one healthcare model—it has several, and they’re all quite different from what we have in the States. Most of the 35 countries in the European Union have single-payer healthcare systems, but the details vary considerably.
Countries like the UK, Sweden, and Norway operate what are essentially single-payer systems where it is solely the government who pays for and provides healthcare services and directly owns most facilities and employs most clinical and related staff with funds from tax contributions. Then you have countries like Germany, and Belgium that use “sickness funds”—these are non-profit funds that don’t market, cherry pick patients, set premiums or rates paid to providers, determine benefits, earn profits or have investors. They’re quasi-public institutions, not private insurance companies like we know them in America. Some systems, such as the Netherlands or Switzerland, rely on mandatory individually purchased private insurance with tight regulation and subsidies, achieving universal coverage with a structured, competitive market.
The French System
France is particularly noted for a successful universal, government-run health insurance system usually described as a single-payer with supplements. All legal residents are automatically covered through the national health insurance program, which is funded by payroll taxes and general taxation.
Most physicians and hospitals are private or nonprofit, not government employees or facilities. Patients generally have free choice of doctors and specialists, though coordinating through a primary care physician improves access and reimbursement. The national insurer pays a large portion of medical costs (often 70–80%), while voluntary private supplemental insurance covers most remaining out-of-pocket expenses such as copays and deductibles.
France is known for spending significantly less per capita than the United States. Cost controls come from nationally negotiated fee schedules and drug pricing rather than limits on access.
What’s striking is that in 2019, US healthcare spending reached $11,072 per person—over double the average of $5,505 across wealthy European nations. Yet despite spending roughly twice as much per person, American health outcomes often lag behind.
The Outcomes Question
This is where the comparison gets uncomfortable for American exceptionalism. The U.S. has the lowest life expectancy at birth among comparable wealthy nations, the highest death rates for avoidable or treatable conditions, and the highest maternal and infant mortality.
In 2023, life expectancy in comparable countries was 82.5 years, which is 4.1 years longer than in the U.S. Japan manages this with healthcare spending at just $5,300 per capita, while Americans spend more than double that amount.
Now, it’s important to note that healthcare systems don’t operate in a vacuum. Life expectancy is influenced by many factors beyond medical care—diet, exercise, smoking, gun violence, drug overdoses, and social determinants of health all play roles. But when you’re spending twice as much and getting worse results, it suggests the system itself might be part of the problem.
Advantages of Single-Payer Systems
The case for single-payer rests on several compelling points. First, administrative simplicity translates to real cost savings. A study found that the administrative burden of health care in the United States was 27 percent of all national health expenditures, with the excess administrative cost of the private insurer system estimated at about $471 billion in 2012 compared to a single-payer system like Canada’s. That’s over $1 out of every $5 of total healthcare spending just going to paperwork, billing disputes, and insurance company profit and overhead before any patient receives care.
Universal coverage is another major advantage. In a properly functioning single-payer system, nobody goes bankrupt from medical bills, nobody delays care because they can’t afford it, and nobody loses coverage when they lose their job. The peace of mind that comes with knowing you’re covered regardless of employment status or pre-existing conditions is difficult to quantify but enormously valuable.
Single-payer systems also have significant negotiating power. When one entity is buying drugs and services for an entire nation, pharmaceutical companies and medical device manufacturers have much less leverage to charge whatever they want. This helps explain why prescription drug prices in other countries are often a fraction of prices in the U.S.
Disadvantages and Trade-offs
The critics of single-payer systems aren’t wrong about everything. Wait times are a genuine concern in some systems. When prices and overall budgets are tightly controlled, some countries experience longer waits for selected elective surgeries, imaging, or specialty visits, especially if investment lags demand.
In 2024, Canadian patients experienced a median wait time of 30 weeks between specialty referral and first treatment, up from 27.2 weeks in 2023, with rural areas facing even longer delays. For procedures like elective orthopedic surgery, patients wait an average of 39 weeks in Canada.
However, it’s crucial to understand that wait times are not a result of the single-payer system itself but of system management, as wait times vary significantly across different single-payer and social insurance systems. Many European countries with universal coverage don’t experience the same wait time issues that plague Canada.
The transition costs are also substantial. Moving from our current system to single-payer would disrupt a massive industry. Over fifteen percent of our economy is related to health care, with half spent by the private sector. Around 160 million Americans currently have insurance through their employers, and transitioning all of them to a government-run plan would be an enormous administrative and political challenge.
A large national payer can be slower to change benefit designs or adopt new payment models; shifting political majorities can affect funding levels and benefit generosity.
Taxes would need to increase significantly to fund such a system, though proponents argue this would be offset by the elimination of insurance premiums, deductibles, and co-pays. It’s essentially a question of whether you’d rather pay through taxes or through premiums—the money has to come from somewhere.
Advantages of America’s Mixed System
Our current system does have some genuine strengths. Innovation thrives in the American healthcare market. The profit motive, for all its flaws, does drive pharmaceutical research and medical device development. American medical schools and research institutions lead the world in many areas of medicine. Academic medical centers and specialty hospitals deliver advanced procedures and complex care that attract patients internationally.
The system also offers more choice for those who can afford it. If you have good insurance, you typically face shorter wait times for elective procedures and can often see specialists without lengthy delays. Americans with high-quality employer-sponsored coverage give their plans relatively high ratings.
Competition between providers can theoretically drive quality improvements, though this effect is often undermined by the complexity of the market and the difficulty consumers face in shopping for healthcare.
Disadvantages of the Current U.S. System
The most glaring problem is simple: The United States remains the only developed country without universal healthcare, and 30 million Americans remain uninsured despite gains under the Affordable Care Act, and many of these gains will soon be lost. Being uninsured in America isn’t just an inconvenience—it can be deadly. People delay care, skip medications, and avoid preventive screenings because of cost concerns.
The administrative complexity is staggering. Doctors spend enormous amounts of time dealing with insurance companies, prior authorizations, and billing disputes. Hospitals employ armies of billing specialists just to navigate the maze of different insurance plans, each with its own rules, formularies, and coverage determinations. U.S. administrative costs account for ~25% of all healthcare spending, among the highest in the world.
Medical bankruptcy is uniquely American. Even people with insurance can find themselves financially devastated by serious illness. High deductibles, surprise bills, and out-of-network charges create a minefield of potential financial catastrophe. Studies of U.S. bankruptcy filings over the past two decades have consistently found that medical bills and medical problems are a major factor in a large share of consumer bankruptcies. Recent summaries suggest that roughly two‑thirds of US personal bankruptcies involve medical expenses or illness-related income loss, and around 17% of adults with health care debt report declaring bankruptcy or losing a home because of that debt.
The system is also profoundly inequitable. Quality of care often depends more on your job, your income, and your zip code than on your medical needs. Out-of-pocket costs per capita have increased as compared to previous decades and the burden falls disproportionately on those least able to afford it.
What Europe Shows Us
The European experience demonstrates that there isn’t one “right” way to achieve universal coverage. The UK’s NHS, Germany’s sickness funds, and France’s hybrid system all manage to cover everyone at roughly half the per-capita cost of American healthcare. Universal Health Coverage exists in all European countries, with healthcare financing almost universally government managed, either directly through taxation or semi-directly through mandated and government-subsidized social health insurance.
They’ve accomplished this through various combinations of centralized negotiation of drug prices, global budgets for hospitals, strong primary care systems that serve as gatekeepers to more expensive specialist care, emphasis on preventive services, and regulation that prevents insurance companies from cherry-picking healthy patients.
Are these systems perfect? No. One of the major disadvantages of centralized healthcare systems is long wait lists to access non-urgent care, though Americans often wait as long or longer for routine primary care appointments as do patients in most universal-coverage countries. Many European countries are wrestling with funding challenges as populations age and expensive new treatments become available. But they’ve solved the fundamental problem that America hasn’t: they ensure everyone has access to healthcare without the risk of financial ruin.
The Path Forward?
The debate over healthcare in America often presents false choices. We don’t have to choose between Canadian-style single-payer and our current system—there are multiple models we could adapt. We could move toward a German-style system with heavily regulated non-profit insurers. We could create a robust public option that competes with private insurance. We could expand Medicare gradually by lowering the eligibility age over time.
What’s clear from international comparisons is that the status quo is unusually expensive and produces mediocre results. We’re paying premium prices for economy outcomes. Whether single-payer is the answer depends partly on your priorities. Do you value universal coverage and cost control more than unlimited choice? Are you willing to accept potentially longer wait times for non-urgent care in exchange for lower costs and universal access? How much do you trust government to manage a program this large?
These aren’t easy questions, and reasonable people disagree. But the evidence from Europe suggests that universal coverage at reasonable cost is achievable—it just requires us to make some choices about what we value most in a healthcare system.
Sources: